Zacks Investment Research downgraded shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) from a hold rating to a strong sell rating in a research report report published on Wednesday.
According to Zacks, “Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. “
A number of other brokerages have also recently commented on SNSS. Cantor Fitzgerald reaffirmed a hold rating and set a $4.00 target price on shares of Sunesis Pharmaceuticals in a report on Thursday, March 8th. ValuEngine cut shares of Sunesis Pharmaceuticals from a sell rating to a strong sell rating in a report on Thursday, March 1st. Oppenheimer began coverage on shares of Sunesis Pharmaceuticals in a report on Thursday, December 14th. They set a buy rating and a $7.00 target price for the company. UBS Group began coverage on shares of Sunesis Pharmaceuticals in a report on Monday, November 20th. They set an outperform rating for the company. Finally, Wells Fargo & Co cut shares of Sunesis Pharmaceuticals from an outperform rating to a market perform rating and reduced their target price for the company from $2.70 to $2.00 in a report on Tuesday, December 5th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Sunesis Pharmaceuticals presently has an average rating of Hold and a consensus target price of $4.00.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.08. analysts predict that Sunesis Pharmaceuticals will post -1.04 EPS for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of Sunesis Pharmaceuticals by 9.5% in the fourth quarter. BlackRock Inc. now owns 130,573 shares of the biopharmaceutical company’s stock worth $482,000 after purchasing an additional 11,351 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of Sunesis Pharmaceuticals by 77.4% in the second quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 18,254 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Sunesis Pharmaceuticals by 4.1% in the second quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock worth $1,635,000 after purchasing an additional 23,819 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Sunesis Pharmaceuticals by 105.2% in the fourth quarter. Geode Capital Management LLC now owns 125,489 shares of the biopharmaceutical company’s stock worth $463,000 after purchasing an additional 64,343 shares in the last quarter. Finally, Vatera Holdings LLC purchased a new stake in shares of Sunesis Pharmaceuticals in the fourth quarter worth $673,000. 53.20% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://stocknewstimes.com/2018/03/15/sunesis-pharmaceuticals-snss-downgraded-by-zacks-investment-research-to-strong-sell.html.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.